Edition:
United States

Astellas Pharma Inc (4503.T)

4503.T on Tokyo Stock Exchange

1,582JPY
20 Apr 2018
Change (% chg)

¥-10 (-0.63%)
Prev Close
¥1,592
Open
¥1,594
Day's High
¥1,596
Day's Low
¥1,577
Volume
4,199,700
Avg. Vol
7,659,810
52-wk High
¥1,637
52-wk Low
¥1,332

Select another date:

Wed, Apr 18 2018

BRIEF-Astellas Announces Sale Of Certain Agensys Research Facilities To Kite, A Gilead Co

* ASTELLAS ANNOUNCES SALE OF CERTAIN AGENSYS RESEARCH FACILITIES TO KITE, A GILEAD COMPANY

BRIEF-Cardurion Pharmaceuticals Licenses Clinical Stage Heart Failure Candidate From Astellas

* CARDURION PHARMACEUTICALS LICENSES CLINICAL STAGE HEART FAILURE CANDIDATE FROM ASTELLAS

BRIEF- Astellas Pharma completes share repurchase

* Says it completes repurchase of 39.6 million shares of its common stock, for 60 billion yen in total, during period from Feb. 1 to March 23

BRIEF-U.S. FDA Grants Priority Review For Supplemental New Drug Application For Xtandi

* U.S. FDA GRANTS PRIORITY REVIEW FOR A SUPPLEMENTAL NEW DRUG APPLICATION (SNDA) FOR XTANDI® (ENZALUTAMIDE) IN NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC)

BRIEF-Astellas Pharma acquires Universal Cells

* Says it has acquired Universal Cells Inc., and will pay up to $102.5 million of upfront and milestones to acquire 100 percent ownership of Universal Cells depending on achievement of certain specified clinical milestones

BRIEF-Astellas acquires Universal Cells Inc

* ASTELLAS WILL PAY UP TO $102.5 MILLION OF UPFRONT AND MILESTONES TO ACQUIRE 100 PERCENT OWNERSHIP OF UNIVERSAL CELLS

BRIEF-Astellas Pharma says top-line results for two phase 3 trials of Peficitinib in rheumatoid arthritis patients

* Says it announced that the results of two phase 3 trials (RAJ3 and RAJ4 trials) on Peficitinib hydrobromide, an oral JAK inhibitor developed by the co, in rheumatoid arthritis patients with an inadequate response to existing therapy, demonstrated superiority over placebo regarding the two trials' primary endpoints

BRIEF-Astellas Pharma says change of chairman and president

* Says it appoints Yoshihiko Hatanaka as new chairman of the board, Kenji Yasukawa as new president and CEO, effective April 1

BRIEF-Astellas Pharma to repurchase up to 2.1 pct shares

* Says it will repurchase up to 42 million shares, representing 2.1 percent of outstanding

BRIEF-Astellas Says To Buy Back Up To 2.08 Percent Of Its Shares For As Much As 60 Billion Yen

* ASTELLAS SAYS TO BUY BACK UP TO 2.08 PERCENT OF ITS SHARES FOR AS MUCH AS 60 BILLION YEN Source text for Eikon: Further company coverage:

Select another date: